Glaucoma Eye Drops & Oral Medications
Medical therapy remains the most common first step in glaucoma treatment. Here's a thorough look at every major drop class, combination drops, oral medications, and how they fit alongside laser and MIGS surgery.
Medical Therapy: The Starting Point for Most Patients
Eye drops remain the most common first-line treatment for glaucoma worldwide, working by either reducing the amount of fluid (aqueous humor) the eye produces, or increasing how efficiently that fluid drains out. Below is a detailed look at every major class used today, in the order most specialists reach for them, followed by combination drops, oral medications, and newer sustained-release options.
Prostaglandin Analogs (First-Line for Most Patients)
Includes latanoprost, travoprost, bimatoprost, tafluprost, and latanoprostene bunod. These once-daily drops increase drainage through the uveoscleral outflow pathway and are typically the most effective single class at lowering pressure, with a favorable safety profile and minimal systemic absorption.
- ✓Common side effects: eyelash growth/thickening, gradual darkening of the iris and skin around the eye, mild redness
- ✓Less common: deepening of the upper eyelid crease over years of use (prostaglandin-associated periorbitopathy)
- ✓Latanoprostene bunod (Vyzulta) adds a nitric-oxide-donating component that also increases outflow through the trabecular meshwork itself
Beta-Blockers
Includes timolol, betaxolol, and levobunolol. These reduce the amount of fluid the eye produces and have been a mainstay of glaucoma treatment for decades. Because they can be absorbed systemically, they require caution in patients with asthma, COPD, slow heart rate, or certain heart conduction problems, and are generally avoided in those patients.
Alpha-2 Adrenergic Agonists
Includes brimonidine and apraclonidine. These reduce fluid production and modestly increase outflow. Brimonidine is commonly used long-term, though a meaningful share of patients develop an allergic-type conjunctivitis with prolonged use, requiring a switch to a different class. Drowsiness and dry mouth can occur, and this class is generally avoided in young children due to the risk of central nervous system depression.
Topical Carbonic Anhydrase Inhibitors
Includes dorzolamide and brinzolamide. These reduce fluid production through a different mechanism than beta-blockers and are often used as an add-on rather than a first choice. Stinging, burning, and a bitter taste after instillation are common complaints, and caution is used in patients with a sulfa allergy.
Rho Kinase Inhibitors
Netarsudil is the newest class of glaucoma drop, working directly on the trabecular meshwork itself to increase outflow — a genuinely different mechanism from older classes. Common side effects include conjunctival redness, small harmless subconjunctival hemorrhages, and a corneal finding called verticillata (whorl-like deposits) that doesn't affect vision.
Miotics (Pilocarpine) & Atropine
Pilocarpine, a cholinergic miotic, constricts the pupil and contracts the ciliary muscle, which pulls the iris away from the drainage angle and can also improve outflow through the trabecular meshwork. It is used far less often today for typical open-angle glaucoma, but retains an important, specific role in narrow-angle and angle-closure glaucoma, where constricting the pupil helps break or prevent pupillary block, often as part of managing an acute attack before or after laser iridotomy.
- ✓Side effects: dim/blurred vision (especially problematic with cataract), brow ache, induced nearsightedness, and an increased retinal detachment risk in highly myopic patients
- ✓Atropine, a cholinergic blocker (the opposite effect of pilocarpine), dilates the pupil and relaxes the ciliary muscle. It has a specific, important role in certain complex glaucomas — most notably malignant glaucoma (aqueous misdirection) — where relaxing and pulling the ciliary body and lens-iris diaphragm backward can deepen the anterior chamber and help resolve the attack
Combination Drops
For patients who need more than one class of medication, several fixed combination drops reduce the number of daily bottles, which meaningfully improves convenience and adherence. Common combinations include timolol/dorzolamide, timolol/brimonidine, brinzolamide/brimonidine, and netarsudil/latanoprost. Each combination carries the side effect profile of both individual components.
Oral Medications
Oral carbonic anhydrase inhibitors (acetazolamide, methazolamide) lower eye pressure more powerfully than any topical drop, but carry a meaningfully higher rate of systemic side effects — tingling in the fingers and toes, metallic taste, fatigue, kidney stones, and, rarely, more serious blood or metabolic effects — so they are generally used short-term, as a bridge before surgery, or during an acute attack, rather than for long-term daily use.
Hyperosmotic agents (oral glycerin, intravenous mannitol) are reserved for emergency treatment of acute angle-closure attacks, rapidly drawing fluid out of the eye to break a severe pressure spike. These are short-term, in-office or hospital treatments, not maintenance therapy, and require caution in patients with heart or kidney disease.
Sustained-Release Drug Delivery
For patients who struggle with the daily discipline drops require, newer sustained-release options place medication directly inside the eye during an in-office or in-operating-room procedure, releasing medication gradually over months. Bimatoprost intracameral implants and travoprost intracameral implants are examples of this newer approach, reducing or eliminating the need for daily drops for a period of time. These are a meaningful option for patients with adherence challenges and are discussed on an individualized basis.
Combining treatments: Eye drops and oral medications are not an either/or choice against laser or surgery. Many patients use drops together with SLT laser, or continue a single drop after MIGS surgery, to reach their target pressure with the lowest overall treatment burden. See our pages on SLT Laser, MIGS Surgery, Trabeculectomy, and Tube Shunt Surgery for how these approaches work together.
Frequently Asked Questions
Do I have to use eye drops forever?
Not necessarily. Many patients reduce or eliminate their drop burden over time with laser treatment (SLT) or MIGS surgery, particularly when combined with cataract surgery. Others do very well on drops alone for life. We tailor this to your specific glaucoma type, severity, and preferences.
Can I combine eye drops with laser or surgery?
Yes. Eye drops, SLT, MIGS, and incisional surgery are not mutually exclusive — many patients use a combination, for example continuing one eye drop after SLT, or after MIGS surgery, if a single treatment doesn't fully reach target pressure. We discuss the full menu of options at every visit, detailed further in our Laser and MIGS Surgery pages.
Why do some drops sting more than others?
Each drop class has a different chemical profile; topical carbonic anhydrase inhibitors and generic prostaglandins are commonly reported to sting or burn more than other classes, while preservative-free formulations can reduce irritation for sensitive patients.
What is pilocarpine used for today?
Pilocarpine, one of the oldest glaucoma medications, is used much less often now than decades ago, but it still has a specific, important role in narrow-angle and angle-closure glaucoma, where it constricts the pupil and pulls the iris away from the drainage angle.
See a glaucoma specialist. Dr. Robert Gunzenhauser is Harvard-educated and UCLA fellowship-trained in glaucoma, providing expert diagnosis and treatment for Eye Drops & Oral Medications at Inland Glaucoma Center in Upland, CA.